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Summary.-A malignant invasive fibrosarcoma in hamsters and a malignant
mammary carcinoma in mice were each challenged with the broad spectrum
proteinase inhibitor aprotinin (Trasylol). In both tumour systems, significant
anti-tumour effects of aprotinin were observed. Variations in the site and dosage
of aprotinin application were made in an attempt to improve the chemotherapeutic
response.
MANY INVESTIGATORS have postulated
that the invasion and metastasis of cells
from a primary malignant tumour were in
some way dependent upon the production
by the tumour of an excess of proteolytic
enzymes (Poole, 1973). Evidence sug-
gesting that proteolytic enzymes could be
directly involved in the malignant state
has come from both in vivo and in vitro
studies. In vivo, collagenases and lyso-
somal enzymes have been identified in
human tumours (Dresden, Heilman and
Schmidt, 1972; Yamanishi, Dabbous and
Hashimoto, 1972; Shamberger and
Rudolph, 1967), and leupeptin (Hozumi
et al., 1972) and synthetic protease
inhibitors have been found to inhibit
tumorigenesis (Troll, Klassen and Janoff,
1970). In vitro, it has been demon-
strated that cancer cells can release
proteolytic enzymes (Holmberg, 1961;
Taylor, Levy and Simpson, 1970), and
that proteases can induce proliferation in
confluent cell cultures (Burger, 1970;
Sefton and Rubin, 1970). On the other
hand, protease inhibitors have been shown
in vitro to restore contact inhibition of
movement (Goetz, XVeinstein and Roberts,
1972) and also to inhibit malignant
invasion (Latner, Longstaff and Pradhan,
1973a). Although recently it was found
that soybean trypsin inhibitor can reduce
the number of recoverable Ehrlich ascites
tumour cells from mice by up to 920%
(W;hur, Robson and Payne, 1973), no
study of the solid tumour controlling
capabilities of a proteinase inhibitor in
vivo has been reported. Consequently, as
a follow-up of our earlier work on in vitro
invasion, we decided to investigate the
effect of aprotinin in malignant ttumours
in mice and hamsters.
MATERIALS AND METHODS
The broad spectrum proteinase inhibitor
used was the naturally occurring polypeptide,
aprotinin (Trasylol, Bayer Pharmaceuticals
Ltd, HaywNards Heath, Sussex).
The cells used to raise invasive tumours in
hamsters were those recovered from the
primary tumours of crude rat liver Iiistone
transformed BHK21/C13 cells (Latner, Long-
staff and Turner, 1973b). These cells were
shown to produce highly malignant tumours
wihich invaded the body wNall and viscera
when re-injected subcutaneously into Syrian
hamsters (Wrights of Essex). Tumours were
initiated by injecting 3 x 105 cells, in 0 5 ml
medium 199 containing 5%0 v/v calf serum
(Flows Laboratories Ltd), into the animals'
left dorso-lumbar region. Tumours, which
were attached to the body wall, became
palpable at the site of inoculation after
4 weeks' incubation.
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Tumours (SMT C3H/He VI) derived from
a spontaneous mammary adenocarcinoma in
a virgin female Heston C3H mouse were
serially propagated by injecting 0-25 ml
tumour homogenate subcutaneously into the
left dorso-lumbar region of inbred female
C3H mice (Heston strain). Tumour growth
could be detected after one week and at this
time the tumours invariably became attached
to the body wall, and frequently invaded the
latter and adjacent tissues.
Following the incubation periods, those
animals with actively growing tumours were
randomly divided into control and test
groups of approximately equal numbers.
Three experiments with hamsters and
2 with mice were conducted, each with
variations in dose or site of application of
aprotinin.
In the first hamster experiment, 2 ml
(20,000 Kallikrein Inactivating Units, KIU)
aprotinin were injected twice daily sub-
cutaneously into the right dorso-lumbar
region close to the tumour. The control
group received similar doses of sterile phos-
phate buffered saline (PBS). At the end of
the third week of treatment all the animals
were sacrificed, the exact wet weight of each
tumour determined and the animal explored
for invasion and metastases by careful
autopsy.
In the second hamster experiment, 1 ml
(10,000 KIU) doses of aprotinin were ad-
ministered intraperitoneally twice daily.
Again, the final wet weights of the tumours
were determined and the animals examined
by autopsy after 3 weeks' treatment. In
addition, the extent of necrosis in each
tumour was estimatedbysectioning randomly
selected pieces of tumour, staining with
haematoxylin and eosin, and outlining in
pencil the projected images on a sheet of
chromatography paper (Whatman 3MM).
The weights of the cut out images of each
tumour section and its corresponding necrotic
area were determined and the percentage
necrosis estimated from the resulting values.
The results in the aprotinin treated tumours
were then compared with the corresponding
control data using the non-parametric stat-
istical technique of Mann and Whitney as
described by Campbell (1967).
In the final hamster experiment, aprotinin
was injected directly into the tumours at
doses of 2 ml, 1 ml or 0 5 ml (20,000, 10,000
or 5000 KIU respectively) twice daily and
sterile ph,ysiological saline at 1 ml doses
injected into the controls.
In the first experiment with mice, 0 5 ml
aprotinin (5000 KIU) was injected twice
daily directly into the tumours for one week
only, and in the second experiment it was
injected subcutaneously into the opposite
flank from the tumour for the first 10 days
of treatment, followed by 1-0 ml twice dailv
for a further 11 days. Similar volumes of
sterile physiological saline were administered
to the controls.
In each experiment, necrosis of the pri-
mary tumour was assessed by cutting it into
small pieces and determining the amount of
necrosis by virtue of the fact that necrotic
material appeared darker in colour and semi-
solid in consistency. In this way, an
approximate estimation of the proportion
of necrotic material could be made. Some
necrosis occurred in the control animals.
On an arbitrary basis, it was therefore
decided to indicate in the tables ofresults, by
a plus sign, necrosis judged to be more than
20% of the tumour mass.
RESULTS
The results from the first hamster
experiment are given in Table I. Whilst
the average weights of the control and
aprotinin treated tumours were 12-2 g and
6-8 g respectively, these values were not
found to be significantly different. How-
ever, in the aprotinin treated group the
tumours appeared to be considerably more
necrotic than in the control group, but
invasion was not entirely inhibited by
aprotinin in this trial.
The data obtained from the second
hamster experiment are presented in
Table II. In this trial, where the apro-
tinin was administered via the peritoneal
cavity, there was no reduction in the
average tumour mass relative to the con-
trols (9.3 g compared with 9-4 g respec-
tively), but invasion was completely in-
hibited and necrosis substantially in-
creased by aprotinin. Estimates of the
extent of necrosis made by weighing the
cut-outs of the projected images yielded
statistically significant results and these
are presented in Table III. It can
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TABLE I.-Effect of the Subcutaneous Administration ofAprotinin on the
Growth ofFibrosarcomata in Hamsters
Control group
A_
Weight of Malignant Tumour
primary (g) invasion necrosis
4-1 - _
4-2 - -
9 0 - _
13-5 - +
16-9 + -
25-5 + -
Aprotinin treated group
Weight of Malignant Tumour
primary (g) invasion necrosis
1-4 - -
4-6 - +
6-2 - +
7-4 - +
10-3 + -
10-8 - +
Animals in the control group received 2 ml PBS twice daily, whereas those in the treated group received
2 ml aprotinin twice daily. In Tables I, II and IV all animals were sacrified after 3 weeks' treatment.
TABLE II.-Effect of the Intraperitoneal Administration ofAprotinin on the
Growth ofFibrosarcomata in Hamsters
Control group Aprotinin treated group
Weight of Malignant Tumour Weight of Malignant Tumour
primary (g) invasion necrosis primary (g) invasion necrosis
5-4 + - 3-6 - -
6-4 - + 5.4 - +
7 0 + - 5.4 +
7-6 - - 87 - +
8-4 + 9-2 - -
8-5 - + 9-2 - +
9-3 - - 96 - +
9-8 - - 105 - +
10*3 + - 11-4 - +
11-8 + - 11-5 - +
13-5 + + 17-3 - +
14-5 +
Animals in the control group received 1 ml PBS twice daily, whereas those in the treated group received
1 ml aprotinin twice daily.
TABLE III.-Effect of the Intraperitoneal Administration ofAprotinin on
Tumour Necrosis
Control group
Total Necrotic %
tumour tumour necrosis
236 25 10-6
172 83 48-3
305 46 15.1
314 44 14-0
230 2 0.9
366 91 24-9
254 13 5.1
306 8 2-6
349 36 10-3
258 14 5-4
236 61 25-8
245 17 6-9
Aprotinin treated group
Total Necrotic %
tumour tumour necrosis
370 66 17-8
277 242 87 -4
299 95 31-8
455 146 32-1
544 94 17-3
318 206 64-8
396 206 52 0
314 250 79 6
219 156 71-2
293 98 33 -4
242 77 31-8
The units for total and necrotic tumour are mg chromatography paper.
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TABLE IV.-Effect ofAprotinin Dose on the Growth ofFibrosarcomata in
Hamsters after Direct Injection into the Tumour
Weight of Malignant Tumour
,atment regimen primary (g) invasion necrosis Comments
% saline twice daily 17-5 + - Extensive invasion of leg
19*4 - -
23-1 + - Invasion of epidermis
29*6 + - Extensive invasion of tho
muscle
rax
2 ml aprotinin twice daily
1 ml aprotinin twice daily
0 5 ml aprotinin twice daily
16-1
16-3
18 -2
11*5
13 -2
27-1
0.0
7 -3
11 *3
20-1
±
+
+
Unweighable necrotic liquid
Invasion of epidermis
Unweighable necrotic liquid
Necrotic sac
Invasion of body wa]l
Necrotic sac
Tumour appeared to be destroyed
Necrotic sac
Necrotic sac
Necrotic sac
TABLE V.-Effect ofAprotinin on the Growth ofAdenocarcinomata in Mice
after Direct Injection into the Tumour
Control group Aprotinin treated group
Tumour
necrosis
+
Weight of
primary (mg)
<10
<10
<10
<10
<10
<10
<10
<10
Malignant Tumour
invasion necrosis
+
+
+
+
Animals in the control group received 0-5 ml of 0.9% saline twice daily, whereas those in the treated
group received 1 ml of aprotinin twice daily. All animals sacrified after 1 week's treatment.
TABLE VI.-Effect of the Subcutaneous Administration ofAprotinin on the
Growth ofAdenocarcinomata in Mice
Control group Aprotinin treated group ~~~~~~~~~~~~~~~~~~~~~~~~~A
Survival Survival
time Weight of Malignant Tumour time Weight of Malignant Tumour
(days) primary (g) invasion necrosis (days) primary (g) invasion necrosis
15 6-6 + 28+ 3-5 +
17 3-0 + 28+ 0-1 -
22 4* 8 + 28+ 4*1 +
22 7-5 + - 28+ 1-2 +
22 5-0 + 28+ 1-6 + 25 6-6 + 28+ 1-0 + 28 12-7 +
- 28+ 6-5 + +
28+ 0-8 - - 28+ 6-9 - + 28+ 0.1 - - 28+ 1*2 - -
The survival time of the mice is given in days following tumour implantation and a + sign indicates
that these animals would have survived longer if permitted. Treatment was started on Day 7 and all
remaining animals were sacrified on Day 28. Animals in the control group received 0.5 ml of 0.9% saline
tWice daily for the first 10 days of treatment and 1.0 ml of 0-9% saline twice daily for the remaining period.
Animals in the treated group received 0-5 ml of aprotinin twice daily for the first 10 days of treatment and
1 D0 ml of aprotinin twice daily for the remaining period.
5
Tre,
1 ml 0.9'
Weight of
pri.mary (mg)
590
<10
640
420
580
<10
Malignant
invasion
±
+
+
A
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be readily appreciated that aprotinin
increased the necrosis of these fibrosarco-
mata (P < 0-01).
In the final hamster trial, where
aprotinin was injected directly into the
tumours, the effects were most encourag-
ing. As can be seen from the results in
Table IV, the lowest dose of aprotinin
used, i.e. 05 ml (5000 KIU) twice daily,
appeared to be the most effective. One
tumour completely disappeared and the
remaining 3 in this group existed only as
necrotic sacs. Histological examination
showed that the control tumours consisted
of solid masses of malignant cells, whereas
the tumours from the aprotinin treated
hamsters showed a good deal of round cell
infiltration and dying tumour material.
Typical examples of these 2 groups are
illustrated in Fig. 1.
Treatment ofthe mammary carcinoma
in mice with aprotinin was no less effec-
tive. In the initial experiment, aprotinin
was injected directly into the tumours and
a considerable reduction in theprogression,
and increase in the necrosis, of the treated
tumours was observed (Table V). Histo-
logical examination of the appropriate
tissues confirmed the initial obvious assess-
ment ofthe state ofthe tumours. As with
the hamster experiment, the treated
tumours showed dying cells and much
round cell infiltration, whereas the
tumours from the untreated animals were
composed of a mass of rapidly growing
cells containing many mitoses. (See Fig.
2 for typical examples of these 2 groups.)
In the second experiment, an initial dose
of 0 5 ml aprotinin (5000 KIU) was in-
jected subcutaneously into the mice twice
daily for the first 10 days oftreatment and
then the dose was doubled for the remain-
der of the experiment. The effectiveness
of this treatment is demonstrated in
Table VI. After one week of continuous
treatment with aprotinin, all of the 9
tumours had regressed, whereas 8 of the 9
mice in the control group carried large
tumours. However, apparent tumour en-
largement in the test group began to occur
after 10 days' treatment, but at autopsy
these masses proved to contain mainly
necrotic material with round cell infiltra-
tion similar to that illustrated in Fig. 2.
DISCUSSION
There seems little doubt that the effect
of aprotinin treatment by any of the
routes we have employed has been to
inhibit the amount of viable tumour
tissue. It has commonly produced mas-
sive tumour necrosis with associated
round cell infiltration and occasionally
virtually complete tumour disappearance.
The mouse carcinoma which we em-
ployed has proven to be highly invasive
and the inhibition of the invasion pheno-
menon by aprotinin was really most
striking. Similar remarks could be made
in relation to the hamster sarcoma, which
we know is also very malignant (Latner
et al., 1973b).
In relation to malignant cells, it has
been suggested that, by the destruction of
the normal surrounding tissue, proteolytic
enzymes play a part in tumour cell
nutrition as well as in invasion and meta-
stasis (Poole, 1973; Latner et al., 1973a).
However, the finding of cellular necrosis
accompanied by marked round cell in-
filtration in both a sarcoma and a carci-
noma treated by aprotinin has led us to
believe that in some way the proteolytic
enzymes of malignant cells may prevent
immunological surveillance. This could
possibly result from digestion of a specific
antibody for the malignant cell, which is
attached to the wall of the T lymphocyte.
The anti-proteinase would prevent this
action and so allow a cellular response to
take place. This would result in the sort
of tumour rejection which we found both
in hamsters and mice.
It could be argued from the findings
in Table V that in the control group 2
out of 6 tumour implants regressed. This
could possibly indicate that the tumour
possessed immunogenic properties and
that a nonspecific immunostimulant, or
cytotoxic substance, could help to bring
about complete tumour regression. We
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do not think this is the case in regard to
the work reported here. In relation to
other experiments in progress, we have
implanted this same tumour into more
than 100 mice of the same C3H strain.
The tumour showed appreciable growth
without regression in 95% of cases.
Moreover, in those animals which received
aprotinin there was marked round cell
infiltration, which did not occur in the
control group.
In view of the success which we have
obtained with animal experiments, a
small number of clinical tests in human
beings has now been instigated. It will,
however, be some considerable time before
any opinion can be expressed with regard
to the possible effectiveness of aprotinin
in the treatment of human malignancy.
We are indebted to Bayer Pharma-
ceuticals Ltd for their generous supply of
aprotinin (Trasylol) used throughout these
investigations and to Dr D. J. Trevan of
the Imperial Cancer Research Labora-
tories, Mill Hill, London, for supplying the
initial sample of mammary carcinoma of
C3H mice. We are also grateful to
Mrs R. Dark for technical assistance with
the animals used in these trials.
The work was financially supported by
the North of England Council of the
Cancer Research Campaign.
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